Key Points
- CEO Dagi Shahar Ben-Noon purchased 14,093 QTEX shares at an average price of $1.49, investing approximately $20,999. This follows purchases of 18,181 shares on October 9 and 168,894 shares on September 28.
- QTEX shares opened at $1.58, compared with a 50-day moving average of $0.98 and a one-year range of $0.28 to $3.85. The company reported a quarterly loss of $0.07 per share and revenue of $0.78 million.
- The company has authorized a buyback of up to 5.6% of its shares, but analyst sentiment remains negative: the stock has a consensus “Sell” rating after recent downgrades.
Inspira Technologies OXY B.H.N. Ltd (NASDAQ:QTEX - Get Free Report) CEO Dagi Ben-Noon bought 14,093 shares of the stock in a transaction that occurred on Tuesday, October 13th. The shares were purchased at an average price of $1.49 per share, for a total transaction of $20,998.57. Following the completion of the acquisition, the chief executive officer owned 14,093 shares of the company's stock, valued at $20,998.57. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Dagi Shahar Ben-Noon also recently made the following trade(s):
- On Friday, October 9th, Dagi Ben-Noon purchased 18,181 shares of Inspira Technologies OXY B.H.N. stock. The shares were purchased at an average cost of $1.67 per share, for a total transaction of $30,362.27.
- On Monday, September 28th, Dagi Ben-Noon purchased 168,894 shares of Inspira Technologies OXY B.H.N. stock. The shares were purchased at an average cost of $0.71 per share, for a total transaction of $119,914.74.
Inspira Technologies OXY B.H.N. Stock Performance
Shares of QTEX stock opened at $1.58 on Wednesday. The company has a quick ratio of 1.62, a current ratio of 2.00 and a debt-to-equity ratio of 0.12. The company has a fifty day moving average price of $0.98. Inspira Technologies OXY B.H.N. Ltd has a one year low of $0.28 and a one year high of $3.85.
Inspira Technologies OXY B.H.N. (NASDAQ:QTEX - Get Free Report) last announced its quarterly earnings data on Thursday, September 24th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.78 million for the quarter.
Inspira Technologies OXY B.H.N. announced that its Board of Directors has initiated a share buyback plan on Monday, June 22nd that permits the company to buy back 2,000,000,000,000 shares. This repurchase authorization permits the company to reacquire up to 5.6% of its stock through open market purchases. Share repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.
Analysts Set New Price Targets
A number of research firms recently commented on QTEX. Wall Street Zen cut Inspira Technologies OXY B.H.N. from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Weiss Ratings downgraded Inspira Technologies OXY B.H.N. from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Sell".
Get Our Latest Stock Report on QTEX
Inspira Technologies OXY B.H.N. Company Profile
(
Get Free Report)
Inspira Technologies OXY B.H.N. Ltd. is a medical technology company focused on developing advanced respiratory-support and blood-monitoring solutions for critical-care settings. The company's technologies are intended to help address complications associated with respiratory failure and improve the management of patients requiring oxygenation support.
Its product portfolio includes the INSPIRA ART system, an extracorporeal respiratory-support platform designed to provide oxygenation while potentially reducing the need for conventional mechanical ventilation or more complex extracorporeal membrane oxygenation procedures.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
